Toinv I completely agree that it was nice to see an RVX NR that didn't mention Don and hopefully, as you allude to, it is symbolic of somewhat of a fresh start. Whatever the reason it has been far too long since we heard something from management that turned out to be accurate. 

I'm not suprised to see Eversana sticking around if they think the science is strong with respect to covid, which they must. Covid success is the only way they get paid under their current deal with RVX. I also think if the next trial is successful they will not have to wait 3 years to start seeing pay out. If Eversana is running the covid program I wouldn't be suprised to see the new trial begin as soon as the FDA response to the type C meeting is received.

It would seem to me that between Eversana, the very respected Covid advisory board and the RVX scientific staff that the new trial will be designed to hit the mark if Apabetalone is indeed covid effective. With the US alone projecting 100 million new covid infections this coming fall/winter I think a drug that can keep those at higher risk out of harms way will be in great demand. To me the fact that Apabetalone has already proven to work well with other medications (such as statins for one) that many of those high risk patients are already on is a huge competitive advantage if it is covid effective. Who knows if it is really effective perhaps the trial might even be stopped early for efficacy. As a non scientist I have to think there must be something positive in the ph2 that is keeping everyone interested. I'm sure Eversana's money and energy is valuable to them as is the time and energy of the RVX covid advisory board.

Perhaps I am wearing rose coloured glasses today.